AV 4025

Drug Profile

AV 4025

Alternative Names: AV4025; ID 4025; PH 4025

Latest Information Update: 02 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AllaChem
  • Class Antivirals; Azoles; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hepatitis C

Most Recent Events

  • 02 Nov 2016 Preclinical trials in Hepatitis C in Russia (PO) before November 2016
  • 08 Apr 2016 Phase-I/II development is ongoing in USA
  • 29 Oct 2013 AllaChem completes a phase I trial in Hepatitis C in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top